BD ameliorates cholestatic liver injury by selectively inhibiting classical BA synthesis, quantitatively remodeling the BA pool toward a less hepatotoxic profile, and suppressing inflammation and fibrosis through functional restoration of FXR-dependent feedback signaling. Its synthesis-centered mechanism and favorable short-term safety profile support BD as a promising therapeutic candidate for cholestatic liver diseases.
Fu et al. (Sat,) studied this question.